ns 1619 has been researched along with 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bondlela, M; Campbell, WB; Deeter, C; Falck, JR; Gauthier, KM; Krishna, UM; Reddy, YK | 1 |
| Alper, SL; Clements, RT; Feng, J; Khabbaz, KR; Liu, Y; Sellke, EW; Sellke, FW; Senthilnathan, V; Sodha, NR | 1 |
| Asano, S; Bender, SB; Borbouse, L; Bratz, IN; Dick, GM; Dincer, UD; Neeb, ZP; Payne, GA; Sturek, M; Tune, JD | 1 |
3 other study(ies) available for ns 1619 and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
| Article | Year |
|---|---|
14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Benzimidazoles; Benzopyrans; Bradykinin; Cattle; Coronary Vessels; Dihydropyridines; Dose-Response Relationship, Drug; Endothelium, Vascular; Iloprost; In Vitro Techniques; Kidney Cortex; Male; Microsomes; Muscle, Smooth, Vascular; Nitroprusside; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 2002 |
Calcium-activated potassium channels contribute to human skeletal muscle microvascular endothelial dysfunction related to cardiopulmonary bypass.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Apamin; Benzimidazoles; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; In Vitro Techniques; Indoles; Intermediate-Conductance Calcium-Activated Potassium Channels; Large-Conductance Calcium-Activated Potassium Channels; Male; Muscle, Skeletal; Oximes; Peptides; Potassium Channels; Potassium Channels, Calcium-Activated; Pyrazoles; Small-Conductance Calcium-Activated Potassium Channels; Vasoconstrictor Agents; Vasodilation | 2008 |
Impaired function of coronary BK(Ca) channels in metabolic syndrome.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 2-Chloroadenosine; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Arterioles; Benzimidazoles; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Signaling; Coronary Circulation; Coronary Vessels; Diet, Atherogenic; Disease Models, Animal; Dose-Response Relationship, Drug; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Large-Conductance Calcium-Activated Potassium Channel beta Subunits; Large-Conductance Calcium-Activated Potassium Channels; Male; Membrane Potentials; Metabolic Syndrome; Microcirculation; Muscle, Smooth, Vascular; Mycotoxins; Nicardipine; Peptides; Phenotype; Potassium Channel Blockers; Swine; Swine, Miniature; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2009 |